VYNE Therapeutics Inc (VYNE) USD0.0001

Sell:$1.60Buy:$1.72$0.03 (1.83%)

Prices delayed by at least 15 minutes
Sell:$1.60
Buy:$1.72
Change:$0.03 (1.83%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.60
Buy:$1.72
Change:$0.03 (1.83%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Key people

David Domzalski
President, Chief Executive Officer, Director
Tyler Zeronda
Chief Financial Officer, Treasurer
Iain Stuart
Chief Scientific Officer
Mutya Fonte Harsch
Chief Legal Officer, General Counsel, Secretary
Patrick G. Lepore
Lead Independent Director
Sharon Barbari
Independent Director
Steven L. Basta
Independent Director
Christine Borowski
Independent Director
Anthony Bruno
Independent Director

Key facts

  • EPIC
    VYNE
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92941V3087
  • Market cap
    $23.27m
  • Employees
    13
  • Shares in issue
    15.21m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.